Evidence map›Paper›PMID 25812472›Full record

ArticlePharmacology, biochemistry, and behavior2015

Prototypical anxiolytics do not reduce anxiety-like behavior in the open field in C57BL/6J mice.

Trey Thompson, Laura Grabowski-Boase, Lisa M Tarantino

Abstract readEvaluation Study
In one paragraph

Article in Pharmacology, biochemistry, and behavior, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Anxiolytic-Pharmaceuticals (Basel, Switzerland) · 2023
    Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. NPAS2 Regulation of Anxiety-Like Behavior and GABAA Receptors.Frontiers in molecular neuroscience · 2017
    Article
  19. Article
  20. Preclinical animal anxiety research - flaws and prejudices.Pharmacology research & perspectives · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Trey ThompsonDivision of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, United States.
Laura Grabowski-BoaseThe Genomics Institute of the Novartis Research Foundation, San Diego, CA, United States.
Lisa M TarantinoDivision of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, United States; Department of Psychiatry, School of Medicine, University of North Carolina, Chapel Hill, NC, United States. Electronic address: lisat@med.unc.edu.
University of North Carolina at Chapel Hill · USGenomics Institute of the Novartis Research Foundation · US

Funding

Organismal and Genetic Networks in Drug Reward and ReinforcementR01DA023690 · NIDA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI TARANTINO, LISA M · 2009 to 2017
$3.0M
NIDA NIH HHS R01 DA023690
6 · The paper itself

Abstract

Understanding and effectively treating anxiety disorders are a challenge for both scientists and clinicians. Despite a variety of available therapies, the efficacy of current treatments is still not optimal and adverse side effects can result in non-compliance. Animal models have been useful for studying the underlying biology of anxiety and assessing the anxiolytic properties of potential therapeutics. The open field (OF) is a commonly used assay of anxiety-like behavior. The OF was developed and validated in rats and then transferred to use in the mouse with only limited validation. The present study tests the efficacy of prototypical benzodiazepine anxiolytics, chlordiazepoxide (CDP) and diazepam (DZ), for increasing center time in the OF in C57BL/6J (B6) mice. Multiple doses of CDP and DZ did not change time spent in the center of the OF. Increasing illumination in the OF did not alter these results. The non-benzodiazepine anxiolytic, buspirone (BUSP) also failed to increase center time in the OF while the anxiogenic meta-chlorophenylpiperazine (mCPP) increased center time. Additional inbred mouse strains, BALB/cJ (BALB) and DBA/2J (D2) did not show any change in center time in response to CDP. Moreover, evaluation of CDP in B6 mice in the elevated plus maze (EPM), elevated zero maze (EZM) and light dark assay (LD) did not reveal changes in anxiety-like behavior while stress-induced hyperthermia (SIH) was decreased by DZ. Pharmacokinetic (PK) studies suggest that adequate CDP is present to induce anxiolysis. We conclude that the measure of center time in the OF does not show predictive validity for anxiolysis in these inbred mouse strains.

Indexed as

AnimalsAnti-Anxiety AgentsAnxietyBehavior, AnimalDisease Models, AnimalHumansMiceMice, Inbred C57BLMotor ActivityPiperazines1-(3-chlorophenyl)piperazineAnti-Anxiety AgentsPiperazinesAnxietyBenzodiazepineC57BL/6JMiceOpen field

Identifiers

PMID25812472
PMCPMC6958708
OpenAlexW1989399273

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.